Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Brady L
Both medications lower A1ca measure of your average blood glucose over the past two to three months 4 but semaglutide typically produces a steeper drop
The launch of Wegovy by Novo Nordisk in the United States as the first-ever oral GLP-1 medication for treating obesity, as well as the advancement of orforglipron by Eli Lilly, will affect competition, as companies strive to develop more convenient and better-tolerated medications that can provide good payer value
Studies have shown that semaglutide can, of course, lead to a significant amount of weight loss, with some people losing up to 15% of their body weight
Adverse events were mainly gastrointestinal, and these were more common with orforglipron than with semaglutide ( Table 1 )
Any questions about tolerability should be directed to your licensed provider
